Inhibition by flavonoids of amyloid-like fibril formation by plasmodium falciparum merozoite surface protein 2

Biochemistry

Volumn 49, Issue 28, 2010, Pages 5899-5908

  Chandrashekaran, Indu R ^a   Adda, Christopher G ^b   MacRaild, Christopher A ^a   Anders, Robin F ^b   Norton, Raymond S ^a  

^a WALTER AND ELIZA HALL INSTITUTE OF MEDICAL RESEARCH   (Australia)

^b LA TROBE UNIVERSITY   (Australia)

Author keywords

[No Author keywords available]

Indexed keywords

AMYLOID FIBRIL; AMYLOID-LIKE FIBRIL; BAICALEIN; BIOPHYSICAL METHODS; CONFORMATIONAL TRANSITIONS; COVALENT MODIFICATIONS; FIBRIL FORMATION; FIBRILLOGENESIS; FLAVONOIDS; FLUORESCENCE ASSAY; GLYCOSYLPHOSPHATIDYLINOSITOL-ANCHORED PROTEINS; HYDROXYL GROUPS; INHIBITORY ACTIVITY; INHIBITORY EFFECT; MALARIA VACCINE; MECHANISTIC PROBES; MEROZOITE SURFACE PROTEINS; MOLECULAR MECHANISM; NMR SPECTROSCOPY; NONCOVALENT BINDING; PHYSIOLOGICAL CONDITION; PLASMODIUM FALCIPARUM; RANDOM COIL; RESVERATROL; SHEET STRUCTURE; SMALL MOLECULE INHIBITOR; STRUCTURAL COMPARISON; SURFACE COAT; THIOFLAVIN T; VACCINE DEVELOPMENT;

BINDING ENERGY; GLYCOPROTEINS; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERIZATION; OLIGOMERS; SCANNING ELECTRON MICROSCOPY; VACCINES;

PROTEINS;

AMYLOID; BAICALEIN; COLLAGEN FIBRIL; EPIGALLOCATECHIN GALLATE; FLAVONOID; MEROZOITE SURFACE PROTEIN 2; OLIGOMER; QUINONE DERIVATIVE; RESVERATROL; THIOFLAVINE;

ARTICLE; AUTOOXIDATION; BETA SHEET; CONFORMATIONAL TRANSITION; COVALENT BOND; DRUG STRUCTURE; ELECTRON MICROSCOPY; FLUORESCENCE; FLUORESCENCE ANALYSIS; INHIBITION KINETICS; NONHUMAN; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; OLIGOMERIZATION; PLASMODIUM FALCIPARUM; PRIORITY JOURNAL; PROTEIN MODIFICATION; SURFACE PROPERTY;

AMYLOID; ANIMALS; ANTIGENS, PROTOZOAN; CATECHIN; CHILD; FLAVONOIDS; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; MALARIA VACCINES; MEMBRANE PROTEINS; MEROZOITES; PLASMODIUM FALCIPARUM; PROTOZOAN PROTEINS;

PLASMODIUM FALCIPARUM;

EID: 77954572992     PISSN: 00062960     EISSN: 15204995     Source Type: Journal    
DOI: 10.1021/bi902197x     Document Type: Article

References (34)

1. Snow, R. W., Guerra, C. A., Noor, A. M., Myint, H. Y., and Hay, S. I. (2005) The global distribution of clinical episodes of Plasmodium falciparum malaria Nature 434, 214-217
2. World Health Organization (2009) World Malaria Report 2009, World Health Organization Press, Geneva.
3. Sachs, J. and Malaney, P. (2002) The economic and social burden of malaria Nature 415, 680-685
4. Smythe, J. A., Coppel, R. L., Brown, G. V., Ramasamy, R., Kemp, D. J., and Anders, R. F. (1988) Identification of two integral membrane proteins of Plasmodium falciparum Proc. Natl. Acad. Sci. U.S.A. 85, 5195-5199
5. Gerold, P., Schofield, L., Blackman, M. J., Holder, A. A., and Schwarz, R. T. (1996) Structural analysis of the glycosyl-phosphatidylinositol membrane anchor of the merozoite surface proteins-1 and -2 of Plasmodium falciparum Mol. Biochem. Parasitol. 75, 131-143
6. Genton, B., Betuela, I., Felger, I., Al-Yaman, F., Anders, R. F., Saul, A., Rare, L., Baisor, M., Lorry, K., Brown, G. V., Pye, D., Irving, D. O., Smith, T. A., Beck, H. P., and Alpers, M. P. (2002) A recombinant blood-stage malaria vaccine reduces Plasmodium falciparum density and exerts selective pressure on parasite populations in a phase 1-2b trial in Papua New Guinea J. Infect. Dis. 185, 820-827
7. Smythe, J. A., Coppel, R. L., Day, K. P., Martin, R. K., Oduola, A. M., Kemp, D. J., and Anders, R. F. (1991) Structural diversity in the Plasmodium falciparum merozoite surface antigen 2 Proc. Natl. Acad. Sci. U.S.A. 88, 1751-1755
8. Fenton, B., Clark, J. T., Khan, C. M., Robinson, J. V., Walliker, D., Ridley, R., Scaife, J. G., and McBride, J. S. (1991) Structural and antigenic polymorphism of the 35- to 48-kilodalton merozoite surface antigen (MSA-2) of the malaria parasite Plasmodium falciparum Mol. Cell. Biol. 11, 963-971
9. Thomas, A. W., Carr, D. A., Carter, J. M., and Lyon, J. A. (1990) Sequence comparison of allelic forms of the Plasmodium falciparum merozoite surface antigen MSA2 Mol. Biochem. Parasitol. 43, 211-220
10. Adda, C. G., Murphy, V. J., Sunde, M., Waddington, L. J., Schloegel, J., Talbo, G. H., Vingas, K., Kienzle, V., Masciantonio, R., Howlett, G. J., Hodder, A. N., Foley, M., and Anders, R. F. (2009) Plasmodium falciparum merozoite surface protein 2 is unstructured and forms amyloid-like fibrils Mol. Biochem. Parasitol. 166, 159-171
11. Zhang, X., Perugini, M. A., Yao, S., Adda, C. G., Murphy, V. J., Low, A., Anders, R. F., and Norton, R. S. (2008) Solution conformation, backbone dynamics and lipid interactions of the intrinsically unstructured malaria surface protein MSP2 J. Mol. Biol. 379, 105-121
12. Low, A., Chandrashekaran, I. R., Adda, C. G., Yao, S., Sabo, J. K., Zhang, X., Soetopo, A., Anders, R. F., and Norton, R. S. (2007) Merozoite surface protein 2 of Plasmodium falciparum: Expression, structure, dynamics, and fibril formation of the conserved N-terminal domain Biopolymers 87, 12-22
13. Yang, X., Adda, C. G., Keizer, D. W., Murphy, V. J., Rizkalla, M. M., Perugini, M. A., Jackson, D. C., Anders, R. F., and Norton, R. S. (2007) A partially structured region of a largely unstructured protein, Plasmodium falciparum merozoite surface protein 2 (MSP2), forms amyloid-like fibrils J. Pept. Sci. 13, 839-848
14. Porat, Y., Abramowitz, A., and Gazit, E. (2006) Inhibition of amyloid fibril formation by polyphenols: Structural similarity and aromatic interactions as a common inhibition mechanism Chem. Biol. Drug Des. 67, 27-37
15. Crozier, A., Jaganath, I. B., and Clifford, M. N. (2009) Dietary phenolics: Chemistry, bioavailability and effects on health Nat. Prod. Rep. 26, 1001-1043
16. Li-Weber, M. (2009) New therapeutic aspects of flavones: The anticancer properties of Scutellaria and its main active constituents Wogonin, Baicalein and Baicalin Cancer Treat. Rev. 35, 57-68
17. Ehrnhoefer, D. E., Bieschke, J., Boeddrich, A., Herbst, M., Masino, L., Lurz, R., Engemann, S., Pastore, A., and Wanker, E. E. (2008) EGCG redirects amyloidogenic polypeptides into unstructured, off-pathway oligomers Nat. Struct. Mol. Biol. 15, 558-566
18. Zhu, M., Rajamani, S., Kaylor, J., Han, S., Zhou, F., and Fink, A. L. (2004) The flavonoid baicalein inhibits fibrillation of α-synuclein and disaggregates existing fibrils J. Biol. Chem. 279, 26846-26857 (Pubitemid 38812518)
19. Hong, D. P., Fink, A. L., and Uversky, V. N. (2008) Structural characteristics of α-synuclein oligomers stabilized by the flavonoid baicalein J. Mol. Biol. 383, 214-223
20. Hudson, S. A., Ecroyd, H., Dehle, F. C., Musgrave, I. F., and Carver, J. A. (2009) (-)-Epigallocatechin-3-gallate (EGCG) maintains κ-casein in its pre-fibrillar state without redirecting its aggregation pathway J. Mol. Biol. 392, 689-700
21. Mandel, S. A., Amit, T., Weinreb, O., Reznichenko, L., and Youdim, M. B. (2008) Simultaneous manipulation of multiple brain targets by green tea catechins: A potential neuroprotective strategy for Alzheimer and Parkinson diseases CNS Neurosci. Ther. 14, 352-365
22. Ehrnhoefer, D. E., Duennwald, M., Markovic, P., Wacker, J. L., Engemann, S., Roark, M., Legleiter, J., Marsh, J. L., Thompson, L. M., Lindquist, S., Muchowski, P. J., and Wanker, E. E. (2006) Green tea (-)-epigallocatechin- gallate modulates early events in huntingtin misfolding and reduces toxicity in Huntington's disease models Hum. Mol. Genet. 15, 2743-2751
23. Jang, J. H. and Surh, Y. J. (2003) Protective effect of resveratrol on β-amyloid-induced oxidative PC12 cell death Free Radical Biol. Med. 34, 1100-1110
24. Radovan, D., Opitz, N., and Winter, R. (2009) Fluorescence microscopy studies on islet amyloid polypeptide fibrillation at heterogeneous and cellular membrane interfaces and its inhibition by resveratrol FEBS Lett. 583, 1439-1445
25. Mishra, R., Sellin, D., Radovan, D., Gohlke, A., and Winter, R. (2009) Inhibiting islet amyloid polypeptide fibril formation by the red wine compound resveratrol ChemBioChem 10, 445-449
26. LeVine, H., III (1999) Quantification of β-sheet amyloid fibril structures with Thioflavin T Methods Enzymol. 309, 274-284
27. 15N chemical shift referencing in biomolecular NMR J. Biomol. NMR 6, 135-140
28. Ermakova, S., Choi, B. Y., Choi, H. S., Kang, B. S., Bode, A. M., and Dong, Z. (2005) The intermediate filament protein vimentin is a new target for epigallocatechin gallate J. Biol. Chem. 280, 16882-16890
29. Paz, M. A., Fluckiger, R., Boak, A., Kagan, H. M., and Gallop, P. M. (1991) Specific detection of quinoproteins by redox-cycling staining J. Biol. Chem. 266, 689-692
30. Hudson, S. A., Ecroyd, H., Kee, T. W., and Carver, J. A. (2009) The Thioflavin T fluorescence assay for amyloid fibril detection can be baised by the presence of exogenous compounds FEBS J. 276, 5960-5972
31. He, Z., Tang, F., Ermakova, S., Li, M., Zhao, Q., Cho, Y. Y., Ma, W. Y., Choi, H. S., Bode, A. M., Yang, C. S., and Dong, Z. (2008) Fyn is a novel target of (-)-epigallocatechin gallate in the inhibition of JB6 Cl41 cell transformation Mol. Carcinog. 47, 172-183
32. Zhou, W., Gallagher, A., Hong, D. P., Long, C., Fink, A. L., and Uversky, V. N. (2009) At low concentrations, 3,4-dihydroxyphenylacetic acid (DOPAC) binds non-covalently to α-synuclein and prevents its fibrillation J. Mol. Biol. 388, 597-610
33. Meng, X., Munishkina, L. A., Fink, A. L., and Uversky, V. N. (2009) Molecular mechanisms underlying the flavonoid-induced inhibition of α-synuclein fibrillation Biochemistry 48, 8206-8224
34. Li, H. T., Lin, D. H., Luo, X. Y., Zhang, F., Ji, L. N., Du, H. N., Song, G. Q., Hu, J., Zhou, J. W., and Hu, H. Y. (2005) Inhibition of α-synuclein fibrillization by dopamine analogs via reaction with the amino groups of α-synuclein. Implication for dopaminergic neurodegeneration FEBS J. 272, 3661-3672